Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Meiling Chen1,2, Yuanzhong Chen1, Kitty Wang2

  • 1Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China.

Clinical and Translational Medicine
|June 17, 2024
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychological responses and cognitive mechanisms of university teachers in using generative AI in teaching: a configurational path analysis based on the MOA framework.

Frontiers in psychology·2026
Same author

Inhibition of ADSS2-mediated de novo AMP biosynthesis re-sensitizes acute myeloid leukemia to BH3 mimetics.

Nature cancer·2026
Same author

BCL-XL drives fibrotic and leukemic progression in myeloproliferative neoplasms.

Frontiers in immunology·2026
Same author

The clinical significance of serum complement fibroblast growth factor 21 in patients with rheumatoid arthritis.

BMC immunology·2026
Same author

Dietary tryptophan supplementation prevents sepsis by enhancing macrophage bacterial defense through GPR37 activation.

Chinese medical journal·2026
Same author

Targeting the METTL1/m7G axis as a therapeutic strategy in myeloid leukemia.

Blood·2026
Same journal

USP43-mediated deubiquitination of SLC7A11 protects against LPS-induced acute lung injury by inhibiting ferroptosis.

Clinical and translational medicine·2026
Same journal

Tumour-macrophage crosstalk initiated by NFIC/METTL3 negative feedback loop via exosomal miR-194-5p promotes NSCLC progression.

Clinical and translational medicine·2026
Same journal

α7nAChR agonist GTS-21 ameliorates sepsis-induced acute kidney injury via MEF2/PGC-1α/HO-1 axis in mice.

Clinical and translational medicine·2026
Same journal

A living biobank of sarcoma patient-derived cell cultures reveals multi-omic and functional insights that capture disease heterogeneity.

Clinical and translational medicine·2026
Same journal

Unveiling non-small cell lung cancer-specific circulating Treg subtype: A paradigm shift in single-cell immunology and its clinical implications.

Clinical and translational medicine·2026
Same journal

Advancing clinical precision medicine via peripheral blood immune single-cell omics.

Clinical and translational medicine·2026
See all related articles

Dysregulated non-N6-methyladenosine (m6A) RNA modifications are crucial in blood cancers. This review details their roles and potential as therapeutic targets in haematological malignancies.

Area of Science:

  • Epitranscriptomics
  • Molecular Biology
  • Oncology

Context:

  • RNA modifications regulate gene expression and cellular functions.
  • Dysregulation of RNA modifications is implicated in various diseases, including haematological malignancies.
  • While N6-methyladenosine (m6A) is well-studied, other non-m6A modifications are gaining attention in blood cancers.

Purpose:

  • To review the roles and implications of non-m6A RNA modifications in haematological malignancies.
  • To summarize the regulatory enzymes and cellular functions of non-m6A RNA modifications.
  • To discuss recent findings on the biological roles and mechanisms of non-m6A modifications in blood cancers.

Summary:

  • Focuses on non-N6-methyladenosine (m6A) RNA modifications, such as N4-acetylcytidine, pseudouridylation, 5-methylcytosine, adenosine to inosine editing, 2'-O-methylation, N1-methyladenosine, and N7-methylguanosine.
Keywords:
epitranscriptomicshaematological malignanciesnon‐m6A RNA modification

Related Experiment Videos

  • Details the enzymes, cellular functions, biological roles, and underlying mechanisms of these modifications in haematological malignancies.
  • Highlights the potential therapeutic strategies targeting non-m6A RNA modification regulators in blood cancers.

    • Impact:

    • Provides a comprehensive overview of non-m6A RNA modifications in haematological malignancies, filling a gap in existing literature.
    • Identifies potential therapeutic targets for treating blood cancers by focusing on dysregulated non-m6A modifiers.
    • Advances the understanding of epitranscriptomic regulation in cancer and opens new avenues for drug development.